This inventor holds 99 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Compounds (CPC class C07D-). Top assignees: Eli Lilly and Company, Constellation Pharmaceuticals, Inc., Athena Neurosciences, Inc.. Active years: 1993-2025.
Inventors with similar research interests:
Location History:
- Indianapolis,, IN (US) (1996)
- Indianpolis, IN (US) (2002)
- Indianapolis, IN (US) (1993 - 2005)
- Zionsville, IN (US) (2008 - 2015)
- Chicago, IL (US) (2016)
- Cambridge, MA (US) (2014 - 2020)
Company Filing History:
60 out of 4,507 
16 out of 56 
6 out of 35 
Years Active: 1993-2025
Areas of Expertise:
Title: James E Audia: Innovative Mind Behind LSD1 Inhibitors and More
Introduction:
James E Audia, based in Indianapolis, IN, is a prolific inventor with a remarkable record of 98 patents to his name. With his contributions in the field of biomedicine, specifically related to LSD1 inhibitors and methyl modifying enzymes, Audia has made significant strides in developing treatments for various diseases and conditions. This article delves into Audia's latest patents, career highlights, notable collaborations, and the impact of his innovative work.
Latest Patents:
Among Audia's recent patents, two notable inventions stand out. The first is related to LSD1 inhibitors and their uses. These novel compounds have shown promise in treating a range of diseases, disorders, and conditions associated with LSD1. The patented formula (I) and its pharmaceutically acceptable salts form the core of this invention. Audia's research paves the way for potential advancements in the treatment of LSD1-related illnesses.
The second invention focuses on modulators of methyl modifying enzymes. This patent introduces agents that can effectively modulate methyl modifying enzymes, offering potential therapeutic applications. By providing compositions and methods of use for these agents, Audia contributes to the ongoing efforts to understand and influence methyl modification processes, leading to new avenues in disease treatments.
Career Highlights:
Over the course of his career, Audia has made significant contributions to the field of biomedicine across various roles. Notably, he has been associated with Eli Lilly and Company, a leading pharmaceutical company renowned for its research and development efforts. Audia's tenure at Eli Lilly and Company suggests a deep involvement in cutting-edge scientific projects and a commitment to advancing medical knowledge and treatments.
Collaborations:
Throughout his professional journey, Audia has collaborated with esteemed colleagues who have contributed to his success. Two notable coworkers who have worked closely with Audia are Jeffrey S Nissen and Lee H Latimer. Their combined expertise and research efforts have likely played a crucial role in the development and realization of Audia's inventive ideas. Collaborations like these demonstrate the importance of teamwork and the power of collective innovation in pushing scientific frontiers.
Conclusion:
Inventor James E Audia exemplifies the spirit of innovation in the field of biomedicine, with an impressive record of 98 patents to his name. His groundbreaking work in developing LSD1 inhibitors and modulators of methyl modifying enzymes holds immense potential for treating various diseases and conditions. Through his collaborations and career highlights, Audia has proven himself to be a notable figure within the pharmaceutical industry. As he continues to explore new avenues and contribute to scientific advancements, Audia's innovative mind is poised to make a lasting impact on the future of healthcare.